[go: up one dir, main page]

MX2017004198A - Composiciones y equipos para tratar prurito y metodos para utilizar los mismos. - Google Patents

Composiciones y equipos para tratar prurito y metodos para utilizar los mismos.

Info

Publication number
MX2017004198A
MX2017004198A MX2017004198A MX2017004198A MX2017004198A MX 2017004198 A MX2017004198 A MX 2017004198A MX 2017004198 A MX2017004198 A MX 2017004198A MX 2017004198 A MX2017004198 A MX 2017004198A MX 2017004198 A MX2017004198 A MX 2017004198A
Authority
MX
Mexico
Prior art keywords
prurite
treat
compositions
equipment
methods
Prior art date
Application number
MX2017004198A
Other languages
English (en)
Inventor
Charles Salamone Joseph
Beal Salamone Aan
Xiaoyu- Chen Leung Kelly
Elizabeth Reilly Katelyn
Original Assignee
Rochal Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rochal Ind Llc filed Critical Rochal Ind Llc
Publication of MX2017004198A publication Critical patent/MX2017004198A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01002—Beta-amylase (3.2.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un tratamiento para prurito que es con base en la amilasa. Las amilasas (a-, ß-, ?- amilasa) se destacan por la escisión de los enlaces a-glicosídicos de polisacáridos, que producen fragmentos de azúcar/carbohidrato de peso molecular más bajo. Se ha encontrado ahora que la a- amilasa es efectiva en la reducción de prurito (picazón) del tejido afectado.
MX2017004198A 2014-10-10 2015-10-08 Composiciones y equipos para tratar prurito y metodos para utilizar los mismos. MX2017004198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/511,988 US20160101166A1 (en) 2014-10-10 2014-10-10 Compositions and kits for treating pruritus and methods of using the same
PCT/US2015/054683 WO2016057789A1 (en) 2014-10-10 2015-10-08 Compositions and kits for treating pruritus and methods of using the same

Publications (1)

Publication Number Publication Date
MX2017004198A true MX2017004198A (es) 2017-07-19

Family

ID=55653769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004198A MX2017004198A (es) 2014-10-10 2015-10-08 Composiciones y equipos para tratar prurito y metodos para utilizar los mismos.

Country Status (11)

Country Link
US (2) US20160101166A1 (es)
EP (1) EP3204038B1 (es)
JP (1) JP6669334B2 (es)
AU (1) AU2015330889B2 (es)
BR (1) BR112017006925B1 (es)
CA (1) CA2963812C (es)
DK (1) DK3204038T3 (es)
ES (1) ES2914615T3 (es)
MX (1) MX2017004198A (es)
PT (1) PT3204038T (es)
WO (1) WO2016057789A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238719B2 (en) 2014-10-10 2019-03-26 Rochal Industries, Llc Compositions and kits for enzymatic debridement and methods of using the same
US9592280B2 (en) * 2014-10-10 2017-03-14 Rochal Industries Llc Compositions and kits for enzymatic debridement and methods of using the same
EP3332776B1 (en) * 2015-08-07 2025-01-22 Kaneka Corporation Patch
RU2647372C1 (ru) * 2017-04-17 2018-03-15 Александр Ливиевич Ураков Крем от обморожений
US20210361820A1 (en) * 2018-01-31 2021-11-25 Systagenix Wound Management, Limited Antimicrobial composition, dressing, dressing components, and method
US11439659B2 (en) * 2018-12-03 2022-09-13 The Regents Of The University Of California Methods and compositions to prevent and treat inflammation and allergic reactions
US10961662B1 (en) 2019-12-23 2021-03-30 Polymer Ventures, Inc. Ash retention additive and methods of using the same
FR3108841B1 (fr) 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
FR3127688B1 (fr) * 2021-10-01 2024-10-04 Algotherapeutix Composition pharmaceutique topique sous forme de gel comprenant au moins de l’amitriptyline pour son utilisation dans le traitement des douleurs neuropathiques induites par un coronavirus
FR3127689B1 (fr) * 2021-10-01 2024-10-04 Algotherapeutix Composition pharmaceutique topique sous forme de gel comprenant au moins de l’amitriptyline pour son utilisation dans le traitement des douleurs neuropathiques du membre fantôme
CN118302226A (zh) * 2021-12-05 2024-07-05 王天欣 治疗瘙痒的方法和装置
CN117919486B (zh) * 2023-12-20 2025-03-14 浙江大学 一种含有自组装活化纳米酶的可注射水凝胶敷料的制备方法及其产品和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2120667A (en) 1937-12-01 1938-06-14 Lakeland Foundation Therapeutic agent for use in the treatment of infection
US2917433A (en) 1956-04-02 1959-12-15 Rystan Company Stable aqueous papain topical compositions
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
US3409719A (en) 1967-05-23 1968-11-05 Baxter Laboratories Inc Debridement agent
WO1984002846A1 (en) 1983-01-21 1984-08-02 Advanced Drug Tech Enzyme ointment
US4719235A (en) 1984-10-16 1988-01-12 Gerald N. Kern Methods and compositions for treating viral infection
US4668228A (en) 1985-03-12 1987-05-26 Johnson & Johnson Products, Inc. Debriding tape
US4885310A (en) 1985-05-09 1989-12-05 Gerald N. Kern Anti-fungal methods and agent
US4717737A (en) 1985-06-05 1988-01-05 Gerald N. Kern Anti-bacterial methods and agent
US4772465A (en) 1986-10-27 1988-09-20 Miles Laboratories, Inc. Method of treating polymicrobial burn wound sepsis with a combination therapy of ciprofloxacin and pseudomonas immune globulin
US5206026A (en) 1988-05-24 1993-04-27 Sharik Clyde L Instantaneous delivery film
US5120656A (en) 1989-08-18 1992-06-09 Osteotech, Inc. Process for debriding bone
CA2041871C (en) * 1990-05-09 2000-07-11 Ruth A. Rosenthal Contact lens cleaning and disinfecting with combinations of polymeric quaternary ammonium compounds and enzymes
US5543149A (en) 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
US5670142A (en) 1996-07-08 1997-09-23 Donald Neudecker Treatment for itch of chicken pox
AU3006899A (en) 1998-03-13 1999-09-27 Biomarin Pharmaceutical Inc. Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US6548556B2 (en) 2000-12-27 2003-04-15 Healthpoint, Ltd. Stable enzymatic wound debrider
US7223386B2 (en) 2002-03-11 2007-05-29 Dow Corning Corporation Preparations for topical skin use and treatment
US20040076671A1 (en) 2002-10-21 2004-04-22 Aletha Tippett Methods and compositions for topical wound treatment
US20070237812A1 (en) * 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US7368128B2 (en) 2003-10-10 2008-05-06 Coloplast A/S Controlled release dressing for enzymatic debridement of necrotic and non-viable tissue in a wound
IL165334A0 (en) 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
WO2008063229A2 (en) 2006-05-12 2008-05-29 Livingston James A Enzymatic debridement therapy for abnormal cell proliferation
US7629158B2 (en) 2006-06-16 2009-12-08 The Procter & Gamble Company Cleaning and/or treatment compositions
US8287858B2 (en) 2006-08-10 2012-10-16 Jon Barron Proteolytic enzyme formulations
WO2010004367A1 (en) 2008-07-10 2010-01-14 Life Science Investments Ltd Use of a mixture of superoxide dismutase and catalase for treating pruritus and alleviating its symptoms
RU2407512C1 (ru) * 2009-06-24 2010-12-27 Сергей Борисович Улитовский Безабразивная зубная паста, содержащая ферменты папаин, декстраназу, альфа-амилазу, калия или аммония тиоцианат, инвертазу или глюкоамилазу, глюкозооксидазу, лактопероксидазу, лизоцим или лактоферрин и лактулозу
US8486664B2 (en) 2010-07-29 2013-07-16 Basf Se Enzymatic production of an ethylenically unsaturated glycoside using polysaccharides
ES2482610T3 (es) 2010-07-29 2014-08-04 Basf Se Procedimiento de producción de glucósidos de derivados de acrilato que emplean polisacáridos y glicosidasas o glicosiltransferasas
US20120104047A1 (en) * 2010-11-01 2012-05-03 Lim Walter K Composition for Relief of Insect Bites and Stings and Apparatus and Method for Its Delivery
CN103687610A (zh) 2011-05-12 2014-03-26 史密夫和内修整形外科股份公司 含有蜂蜜曲霉蛋白酶的伤口清创组合物和使用其治疗伤口的方法
WO2013016255A1 (en) 2011-07-28 2013-01-31 3M Innovative Properties Company Wound-healing compositions and method of use
WO2013116732A1 (en) * 2012-02-02 2013-08-08 Curelon Llc Enzyme compositions and use thereof for wound healing
WO2013155476A1 (en) 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
US20130287859A1 (en) 2012-04-26 2013-10-31 Lescarden Inc. Method for treating prupritus with cartilage extract
CN102973927A (zh) * 2012-11-29 2013-03-20 李安平 止痒卫生纸制造方法
US20150086529A1 (en) 2013-09-26 2015-03-26 Barbara Ann Hillenbrand Therapeutic Burn Gel

Also Published As

Publication number Publication date
CA2963812A1 (en) 2016-04-14
BR112017006925A2 (pt) 2017-12-12
JP6669334B2 (ja) 2020-03-18
DK3204038T3 (da) 2022-06-13
PT3204038T (pt) 2022-06-06
AU2015330889A1 (en) 2017-04-27
ES2914615T3 (es) 2022-06-14
EP3204038A1 (en) 2017-08-16
US10688159B2 (en) 2020-06-23
NZ730769A (en) 2024-02-23
BR112017006925B1 (pt) 2023-12-12
US20160199459A1 (en) 2016-07-14
EP3204038A4 (en) 2018-06-13
EP3204038B1 (en) 2022-05-04
JP2017530164A (ja) 2017-10-12
WO2016057789A1 (en) 2016-04-14
US20160101166A1 (en) 2016-04-14
CA2963812C (en) 2025-05-06
AU2015330889B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MX2017004198A (es) Composiciones y equipos para tratar prurito y metodos para utilizar los mismos.
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
NI201600164A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX2017011241A (es) Metodos para tratar la piel.
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
BR112017006664A2 (pt) terapias de combinação
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
NI201500143A (es) Derivados de oxopiridinas sustituida y usos de los mismos en el tratamiento de trastornos cardivasculares.
MX387055B (es) Agonistas del receptor de apelina (apj) y usos de los mismos.
MX2019001718A (es) Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX391935B (es) Anticuerpos inhibidores de via del factor tisular y usos de los mismos.
BR112016029558A2 (pt) terapia de células-tronco em patologias endometriais
MX2015011688A (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
MX2016014050A (es) Combinacion de un acido hialuronico y un polisacarido sulfatado.
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
MX2017004199A (es) Composiciones y equipos para desbridamiento enzimatico y metodos para usar los mismos.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.